SeekingAlpha · Sep 9, 2026
NYSE · RVTY
Revvity, Inc.
Healthcare · Medical - Diagnostics & Research
$140.19
Up+$11.70 (+9.11%)
Updated Sep 16, 2026, 12:16 PM
SID Score
6.6/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 12.32B
- P/E ratio
- 51.31
- Dividend yield
- 0.25%
- 52-week range
- $81.22 – $140.22
- Volume
- 3.69M
- Avg. volume
- 1.43M
Price performance
RVTY price history
1M range · 20 trading sessions · Daily adjusted prices
RVTY closed at $140.19 after 20 trading sessions, up 23.24% for the selected period.
- Last close
- $140.19
- Period change
- +23.24%
- Period low
- $113.75
- Period high
- $140.19
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $128.67 | $140.22 | $128.67 | $140.19 | 3.69M |
| Sep 14, 2026 | $124.69 | $128.70 | $123.95 | $128.49 | 1.9M |
| Sep 11, 2026 | $122.40 | $124.65 | $121.61 | $124.31 | 1.15M |
| Sep 10, 2026 | $122.77 | $123.23 | $120.895 | $120.94 | 1.34M |
| Sep 9, 2026 | $125.77 | $126.655 | $121.20 | $123.85 | 1.88M |
| Sep 8, 2026 | $128.50 | $129.54 | $126.89 | $127.08 | 1.5M |
| Sep 4, 2026 | $130.03 | $131.70 | $129.56 | $130.22 | 1.18M |
| Sep 3, 2026 | $132.45 | $133.00 | $127.78 | $130.63 | 1.82M |
| Sep 2, 2026 | $125.94 | $131.75 | $125.94 | $130.94 | 2.1M |
| Sep 1, 2026 | $127.46 | $128.18 | $125.49 | $126.59 | 3.06M |
| Aug 31, 2026 | $127.34 | $128.815 | $125.456 | $128.67 | 1.63M |
| Aug 28, 2026 | $128.57 | $130.07 | $127.26 | $128.80 | 1.58M |
| Aug 27, 2026 | $126.53 | $129.80 | $126.50 | $129.71 | 1.93M |
| Aug 26, 2026 | $123.29 | $126.90 | $123.29 | $126.35 | 1.16M |
| Aug 25, 2026 | $123.69 | $124.94 | $122.0109 | $124.84 | 1.04M |
| Aug 24, 2026 | $123.49 | $124.89 | $121.38 | $123.00 | 1.51M |
| Aug 21, 2026 | $124.48 | $124.97 | $121.51 | $124.75 | 2.29M |
| Aug 20, 2026 | $118.26 | $124.49 | $116.955 | $124.13 | 2.34M |
| Aug 19, 2026 | $116.02 | $122.11 | $115.29 | $119.45 | 1.72M |
| Aug 18, 2026 | $115.86 | $115.90 | $113.69 | $113.75 | 800.03K |
Latest RVTY news
The latest Smart Investors Daily articles mentioning RVTY.
Stock researchCompany · Overview
RVTY research
Overview
Company profile and research snapshot.
Company profile
Revvity is a global life sciences and diagnostics company formed in 2023 following the rebranding of PerkinElmer. The company operates in two segments: life sciences, which provides reagents and instruments for biopharma and academic research, and signals software, and diagnostics, which offers tools in immunodiagnostics and newborn and reproductive health. Revvity's products and services are sold worldwide, with major markets in the US, Europe, and China.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $110.25
- Implied upside
- —
- Analysts
- 25
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 4, 2026 | Keybanc | Overweight | — |
| Sep 1, 2026 | RBC Capital | Sector Perform | — |
| Aug 5, 2026 | Evercore ISI Group | Outperform | — |
| Jul 6, 2026 | Evercore ISI Group | Outperform | — |
| Jun 26, 2026 | Bernstein | Market Perform | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 9, 2026
Revvity to Acquire Human Cell Design to Advance Human-Relevant Cell Models for Metabolic Disease Drug Discovery
WALTHAM, Mass., September 09, 2026--Revvity, Inc. (NYSE: RVTY) today announced it has entered into a definitive agreement to acquire Human Cell Design (HCD), a France-based biotechnology company specializing in human cell models and preclinical research solutions for diabetes, obesity and other metabolic diseases. The acquisition is expected to add HCD’s human pancreatic beta cell models to Revvity’s Life Sciences portfolio, supporting drug discovery, screening and preclinical research, includin
Benzinga · Sep 9, 2026
UBS Assumes Revvity at Neutral, Raises Price Target to $140
UBS analyst Doug Schenkel assumes Revvity (NYSE:RVTY) with a Neutral rating and raises Price Target to $140.
Benzinga · Sep 9, 2026
Revvity Bets on GLP-1 Boom With Human Cell Design Acquisition
Revvity buys Human Cell Design to expand diabetes and GLP-1 drug discovery tech. Acquisition expected to close in Q4 2026.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
